
(AGENPARL) – SILVER SPRING mar 20 giugno 2023 FDA approves talazoparib with enzalutamide for HRR gene-mutated metastatic castration-resistant prostate cancer
Fonte/Source: http://www.fda.gov/drugs/drug-approvals-and-databases/fda-approves-talazoparib-enzalutamide-hrr-gene-mutated-metastatic-castration-resistant-prostate